Nefiracetam
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529303

CAS#: CAS#77191-36-7

Description: Nefiracetam is a GABA receptor agonist potentially for the treatment of epilepsy.


Price and Availability

Size Price Shipping out time Quantity
200mg USD 280 2 Weeks
1g USD 680 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-09-28. Prices are subject to change without notice.

Nefiracetam, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 529303
Name: Nefiracetam
CAS#: CAS#77191-36-7
Chemical Formula: C14H18N2O2
Exact Mass: 246.1368
Molecular Weight: 246.31
Elemental Analysis: C, 68.27; H, 7.37; N, 11.37; O, 12.99


Synonym: DM-9384; DZL-221; DM9384; DZL221; DM 9384; DZL 221

IUPAC/Chemical Name: N-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide

InChi Key: NGHTXZCKLWZPGK-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)

SMILES Code: O=C(NC1=C(C)C=CC=C1C)CN2C(CCC2)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Omotuyi OI, Ueda H. Molecular dynamics study-based mechanism of nefiracetam-induced NMDA receptor potentiation. Comput Biol Chem. 2015 Apr;55:14-22. doi: 10.1016/j.compbiolchem.2015.01.004. PubMed PMID: 25659913.

2: Starkstein SE, Brockman S, Hatch KK, Bruce DG, Almeida OP, Davis WA, Robinson RG. A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy. J Stroke Cerebrovasc Dis. 2016 May;25(5):1119-27. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.032. PubMed PMID: 26915605.

3: Moriguchi S, Han F, Shioda N, Yamamoto Y, Nakajima T, Nakagawasai O, Tadano T, Yeh JZ, Narahashi T, Fukunaga K. Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice. J Neurochem. 2009 Jul;110(1):170-81. doi: 10.1111/j.1471-4159.2009.06122.x. PubMed PMID: 19457128.

4: Moriguchi S, Zhao X, Marszalec W, Yeh JZ, Fukunaga K, Narahashi T. Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Neuroscience. 2009 May 5;160(2):484-91. doi: 10.1016/j.neuroscience.2009.02.055. PubMed PMID: 19272425.

5: Moriguchi S, Shioda N, Han F, Narahashi T, Fukunaga K. CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region. J Neurochem. 2008 Aug;106(3):1092-103. doi: 10.1111/j.1471-4159.2008.05440.x. PubMed PMID: 18445137.

6: Moriguchi S, Shioda N, Maejima H, Zhao X, Marszalec W, Yeh JZ, Fukunaga K, Narahashi T. Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Mol Pharmacol. 2007 Feb;71(2):580-7. PubMed PMID: 17095583.

7: Robinson RG, Jorge RE, Clarence-Smith K. Double-blind randomized treatment of poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2008 Spring;20(2):178-84. doi: 10.1176/appi.neuropsych.20.2.178. PubMed PMID: 18451188.

8: Fu CY, He XY, Li XF, Zhang X, Huang ZW, Li J, Chen M, Duan CZ. Nefiracetam Attenuates Pro-Inflammatory Cytokines and GABA Transporter in Specific Brain Regions of Rats with Post-Ischemic Seizures. Cell Physiol Biochem. 2015;37(5):2023-31. doi: 10.1159/000438562. PubMed PMID: 26584300.

9: Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam. J Neuropsychiatry Clin Neurosci. 2009 Spring;21(2):144-51. doi: 10.1176/appi.neuropsych.21.2.144. PubMed PMID: 19622685.

10: Han F, Nakano T, Yamamoto Y, Shioda N, Lu YM, Fukunaga K. Improvement of depressive behaviors by nefiracetam is associated with activation of CaM kinases in olfactory bulbectomized mice. Brain Res. 2009 Apr 10;1265:205-14. doi: 10.1016/j.brainres.2009.02.014. PubMed PMID: 19233146.

11: Kitano Y, Komiyama C, Makino M, Takasuna K, Satoh H, Aoki T, Kinoshita M, Takazawa A, Yamauchi T, Sakurada S. Anticonvulsant and neuroprotective effects of the novel nootropic agent nefiracetam on kainic acid-induced seizures in rats. Brain Res. 2005 Sep 28;1057(1-2):168-76. PubMed PMID: 16122714.

12: Lu XC, Dave JR, Chen Z, Cao Y, Liao Z, Tortella FC. Nefiracetam attenuates post-ischemic nonconvulsive seizures in rats and protects neuronal cell death induced by veratridine and glutamate. Life Sci. 2013 Jun 13;92(22):1055-63. doi: 10.1016/j.lfs.2013.04.004. PubMed PMID: 23603142.

13: Tsuchiya Y, Yabe K, Takada S, Ishii Y, Jindo T, Furuhama K, Suzuki KT. Early pathophysiological features in canine renal papillary necrosis induced by nefiracetam. Toxicol Pathol. 2005;33(5):561-9. PubMed PMID: 16105799.

14: Ando T, Takagi N, Takagi K, Kago T, Takeo S. Effects of nefiracetam on the levels of brain-derived neurotrophic factor and synapsin I mRNA and protein in the hippocampus of microsphere-embolized rats. Eur J Pharmacol. 2005 Jan 10;507(1-3):49-56. PubMed PMID: 15659294.

15: Yoshii M, Furukawa T, Ogihara Y, Watabe S, Shiotani T, Ishikawa Y, Nishimura M, Nukada T. Negative regulation of opioid receptor-G protein-Ca2+ channel pathway by the nootropic nefiracetam. Ann N Y Acad Sci. 2004 Oct;1025:389-97. PubMed PMID: 15542741.

16: Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J Pharmacol Exp Ther. 2003 Oct;307(1):160-7. PubMed PMID: 12805478.

17: Woodruff-Pak DS, Ewers M, Shiotani T, Watabe S, Tanaka M, Wenk GL. Nefiracetam and physostigmine: separate and combined effects on learning in older rabbits. Neurobiol Aging. 2004 Jul;25(6):807-16. PubMed PMID: 15165705.

18: Yan Y, Mizuno T, Nitta A, Yamada K, Nabeshima T. Nefiracetam attenuates methamphetamine-induced discriminative stimulus effects in rats. Ann N Y Acad Sci. 2004 Oct;1025:274-8. PubMed PMID: 15542727.

19: Takeo S, Fukatsu T, Miyake-Takagi K, Takagi N, Niimura M, Nagakura A, Ando T, Tanonaka K. Persistent effects of delayed treatment with nefiracetam on the water maze task in rats with sustained cerebral ischemia. J Pharmacol Exp Ther. 2003 Feb;304(2):513-23. PubMed PMID: 12538802.

20: Tsuchiya Y, Tominaga Y, Matsubayashi K, Jindo T, Furuhama K, Suzuki KT. Investigation on urinary proteins and renal mRNA expression in canine renal papillary necrosis induced by nefiracetam. Arch Toxicol. 2005 Sep;79(9):500-7. PubMed PMID: 16007418.